FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2598071611> ?p ?o ?g. }

• W2598071611 endingPage "492" @default.
• W2598071611 startingPage "492" @default.
• W2598071611 abstract "492 Background: Immuno-oncology (IO) checkpoint inhibitors have demonstrated efficacy in metastatic renal cell cancer (mRCC) treatment. Real world data is required to assess outcomes when applied to the general population. Methods: A retrospective analysis was performed using the IMDC database. It included mRCC patients treated with IO agents, including atezolizumab (Atezo), avelumab, ipilimumab, nivolumab (Nivo), and pembrolizumab (Pembro). Some patients were treated with combination therapy with a targeted agent. Patients may have received IO therapy as first-, second-, third-, or fourth-line treatment. Overall survival (OS), treatment duration, and overall response rates (ORR) were calculated. Results: 255 patients with mRCC treated with IO therapy were included. The ORR to IO therapy in those patients who were evaluable was 29% (32% first-, 22% second-, 33% third-, and 32% fourth-line therapy). Patients treated with second-line IO therapy were divided into favorable, intermediate, and poor risk using IMDC criteria; the corresponding median OS rates were not reached, 26.7 mo, and 12.1 mo, respectively (p<0.0001). Conclusions: Response rates to IO therapies appear to remain consistent no matter which line of therapy it is used in. Within second-line treatment, IMDC criteria appear to stratify patients appropriately into favorable, intermediate, and poor risk groups. Survival data are premature and will be updated. In contrast to Nivo clinical trial data, where median treatment duration was 5.5 mo, longer treatment length is observed in real world practice. [Table: see text]" @default.
• W2598071611 created "2017-04-07" @default.
• W2598071611 creator A5013185325 @default.
• W2598071611 creator A5018910230 @default.
• W2598071611 creator A5023028363 @default.
• W2598071611 creator A5025529463 @default.
• W2598071611 creator A5028194267 @default.
• W2598071611 creator A5028872384 @default.
• W2598071611 creator A5036213851 @default.
• W2598071611 creator A5037060013 @default.
• W2598071611 creator A5037495975 @default.
• W2598071611 creator A5037646183 @default.
• W2598071611 creator A5052504518 @default.
• W2598071611 creator A5058331275 @default.
• W2598071611 creator A5064078958 @default.
• W2598071611 creator A5068966220 @default.
• W2598071611 creator A5076375756 @default.
• W2598071611 creator A5077514210 @default.
• W2598071611 creator A5082537363 @default.
• W2598071611 creator A5082601600 @default.
• W2598071611 creator A5087836779 @default.
• W2598071611 creator A5089375452 @default.
• W2598071611 date "2017-02-20" @default.
• W2598071611 modified "2023-10-02" @default.
• W2598071611 title "Real world experience of immuno-oncology agents in metastatic renal cell carcinoma: Results from the IMDC." @default.
• W2598071611 doi "https://doi.org/10.1200/jco.2017.35.6_suppl.492" @default.
• W2598071611 hasPublicationYear "2017" @default.
• W2598071611 type Work @default.
• W2598071611 sameAs 2598071611 @default.
• W2598071611 citedByCount "6" @default.
• W2598071611 countsByYear W25980716112018 @default.
• W2598071611 countsByYear W25980716112021 @default.
• W2598071611 countsByYear W25980716112022 @default.
• W2598071611 countsByYear W25980716112023 @default.
• W2598071611 crossrefType "journal-article" @default.
• W2598071611 hasAuthorship W2598071611A5013185325 @default.
• W2598071611 hasAuthorship W2598071611A5018910230 @default.
• W2598071611 hasAuthorship W2598071611A5023028363 @default.
• W2598071611 hasAuthorship W2598071611A5025529463 @default.
• W2598071611 hasAuthorship W2598071611A5028194267 @default.
• W2598071611 hasAuthorship W2598071611A5028872384 @default.
• W2598071611 hasAuthorship W2598071611A5036213851 @default.
• W2598071611 hasAuthorship W2598071611A5037060013 @default.
• W2598071611 hasAuthorship W2598071611A5037495975 @default.
• W2598071611 hasAuthorship W2598071611A5037646183 @default.
• W2598071611 hasAuthorship W2598071611A5052504518 @default.
• W2598071611 hasAuthorship W2598071611A5058331275 @default.
• W2598071611 hasAuthorship W2598071611A5064078958 @default.
• W2598071611 hasAuthorship W2598071611A5068966220 @default.
• W2598071611 hasAuthorship W2598071611A5076375756 @default.
• W2598071611 hasAuthorship W2598071611A5077514210 @default.
• W2598071611 hasAuthorship W2598071611A5082537363 @default.
• W2598071611 hasAuthorship W2598071611A5082601600 @default.
• W2598071611 hasAuthorship W2598071611A5087836779 @default.
• W2598071611 hasAuthorship W2598071611A5089375452 @default.
• W2598071611 hasConcept C121608353 @default.
• W2598071611 hasConcept C126322002 @default.
• W2598071611 hasConcept C143998085 @default.
• W2598071611 hasConcept C2775949291 @default.
• W2598071611 hasConcept C2777381376 @default.
• W2598071611 hasConcept C2777472916 @default.
• W2598071611 hasConcept C2777701055 @default.
• W2598071611 hasConcept C2780030458 @default.
• W2598071611 hasConcept C2780057760 @default.
• W2598071611 hasConcept C2781433595 @default.
• W2598071611 hasConcept C2908647359 @default.
• W2598071611 hasConcept C71924100 @default.
• W2598071611 hasConcept C99454951 @default.
• W2598071611 hasConceptScore W2598071611C121608353 @default.
• W2598071611 hasConceptScore W2598071611C126322002 @default.
• W2598071611 hasConceptScore W2598071611C143998085 @default.
• W2598071611 hasConceptScore W2598071611C2775949291 @default.
• W2598071611 hasConceptScore W2598071611C2777381376 @default.
• W2598071611 hasConceptScore W2598071611C2777472916 @default.
• W2598071611 hasConceptScore W2598071611C2777701055 @default.
• W2598071611 hasConceptScore W2598071611C2780030458 @default.
• W2598071611 hasConceptScore W2598071611C2780057760 @default.
• W2598071611 hasConceptScore W2598071611C2781433595 @default.
• W2598071611 hasConceptScore W2598071611C2908647359 @default.
• W2598071611 hasConceptScore W2598071611C71924100 @default.
• W2598071611 hasConceptScore W2598071611C99454951 @default.
• W2598071611 hasIssue "6_suppl" @default.
• W2598071611 hasLocation W25980716111 @default.
• W2598071611 hasOpenAccess W2598071611 @default.
• W2598071611 hasPrimaryLocation W25980716111 @default.
• W2598071611 hasRelatedWork W2615260918 @default.
• W2598071611 hasRelatedWork W2800311363 @default.
• W2598071611 hasRelatedWork W2968490685 @default.
• W2598071611 hasRelatedWork W2981325621 @default.
• W2598071611 hasRelatedWork W3106449294 @default.
• W2598071611 hasRelatedWork W3163671397 @default.
• W2598071611 hasRelatedWork W3216520672 @default.
• W2598071611 hasRelatedWork W3216625399 @default.
• W2598071611 hasRelatedWork W4211037971 @default.
• W2598071611 hasRelatedWork W4283460237 @default.
• W2598071611 hasVolume "35" @default.
• W2598071611 isParatext "false" @default.
• W2598071611 isRetracted "false" @default.

• next